| |
|
 |
|
MODERN RHEUMATOLOGY Vol.12 No.4
>MR12-4
|
| Cyclosporin A therapy for interstitial pneumonitis associated with rheumatic disease |
|
| Y. Tokano1, H. Ogasawara1, S. Ando1, T. Fujii1, H. Kaneko1, N. Tamura1, T. Yano1, K. Hirokawa1, T. Fukazawa1, A. Murashima1, S. Kobayashi1, I. Sekigawa1, Y. Takasaki1, N. Iida1, H. Hashimoto1 |
(1) Department of Rheumatology and Internal Medicine, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan |
| |
Full Text
> Click Here （member's only） |
| |
| Abstract |
| Abstract To determine the efficacy of cyclosporin A (CysA) for the treatment of steroid-resistant interstitial pneumonitis (IP), we enrolled 25 patients with various rheumatic diseases and steroid-resistant IP in a pilot study [4 patients with rheumatoid arthritis (RA), 2 with systemic lupus erythematosus (SLE), 11 with polymyositis/dermatomyositis (PM/DM), 4 with systemic sclerosis (SSc), 1 with mixed connective tissue disease (MCTD), 3 with Sjogren syndrome (SS)]. Twelve patients (48%) showed a persistent response to CysA therapy, and 7 of them had PM/DM, including so-called amyopathic DM. Patients with a persistent response had moderately elevated lactate dehydroxygenase (LDH) levels, whereas patients who died had much higher LDH levels and hypoxia. Even patients with low blood levels of CysA achieved a persistent response. In responding patients, the symptoms, chest X-ray findings, arterial oxygen tension, and LDH level all improved after less than 4 weeks. In conclusion, CysA seem to be useful for treating patients with steroid-resistant IP, whose duration is short and severity is mild. |
| |
| Key words |
| Key words Cyclosporin A ・ Interstitial pneumonitis (IP) ・ Polymyositis/dermatomyositis (PM/DM) ・ Systemic sclerosis (SSc) |
|
| |
| 一覧に戻る |
|
|
